How Is Solventum's Stock Performance Compared to Other Healthcare Stocks

Eagan, Minnesota-based Solventum Corporation (SOLV) is an independent healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. The company has a market capitalization of $15 billion and operates in three segments: Medsurg, Dental Solutions, and Health Information Systems. 

Companies with a market cap of $10 billion or more are typically called “large-cap stocks.” SOLV fits squarely into that category, with a market cap above this threshold that reflects its substantial size and influence in the medical instruments and supplies industry.   

However, the stock currently trades 5.9% below its 52-week high of $94.16 recorded on Sept. 1. SOLV has grown 17.2% over the past three months, outperforming the State Street Healthcare Select Sector SPDR ETF’s (XLV) 10.8% rise during the same time frame.     

In the longer term, SOLV has delivered a different performance. The stock has grown 23.4% over the past 52 weeks, underperforming the 24.6% surge of XLV over the same period. SOLV has been trading above its 200-day moving average since June and has also been mostly above its 50-day moving average since July, indicating bullish momentum. 

SOLV’s short-term outperformance can be linked to its impressive Q2 2026 earnings. The company’s revenue for the quarter came in at $2.2 billion, surpassing the Street’s estimates. Moreover, its adjusted EPS amounted to $2.55, also topping the consensus estimates. The company also raised its full-year outlook, increasing organic sales growth guidance to 2.50%-3% and its adjusted EPS guidance to $7.10-$7.20. Management cited the increasing integration of AI and robotics into surgical procedures and an aging population in the coming years as tailwinds for the next few years. 

When stacked against its rival, Becton, Dickinson and Company (BDX) has surged 22.5% over the past year, underperforming SOLV.  

Wall Street’s view of SOLV stock is somewhat bullish. Among the 16 analysts covering the stock, the overall consensus rating is “Moderate Buy.” Its mean price target of $93.60 offers a 5.7% upside potential.   

On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.